Mesoblast - Moving closer to key catalysts
Mesoblast is approaching some very key catalysts. The company expects to complete its filing of Remestemcel-L in pediatric acute graft versus host...
1.2k Views
Mesoblast - Increasingly positive on aGvHD
With a positive primary endpoint plus 180-day data in acute graft versus host disease (aGvHD), Mesoblast is on track for its first US approval....
1.1k Views
Australia Short Interest - August in Review
Of the 134 companies that reported annual results in August, 65% missed their targets on the top line and just over half reported a rise in profits...
550 Views
Raising FVE for Mesoblast After Adjusting for AUD as We Await 180 Day Survival Data in AGvHD
We are raising our fair value estimate for no-moat Mesoblast Ltd (MSB AU) to AUD 2.90 from AUD 2.60 previously, after adjusting for the recent...
528 Views
Mesoblast Books First-Half Profit and Moves Closer to FDA Approval in Pediatric AGvHD
No-moat Mesoblast Ltd (MSB AU) achieved a financial milestone in the first six months of fiscal 2018 by posting a maiden net profit after tax of...
193 Views